92 NO:18, SEQ ID NO:20, SEQ ID NO:22, or SEQ ID NO:24 have at least 90% identity based on the Clustal alignment method.

13. The polynucleotide of claim 11 comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, or SEQ ID NO:23.

14. The polynucleotide of claim 11, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, or SEQ ID NO:24.

15. The polynucleotide of claim 11, wherein the polypeptide is a sucrose transport protein.

16. An isolated polypeptide, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, or SEQ ID NO:24 have at least 95% identity based on the Clustal alignment method.

17. The polypeptide of Claim 16, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, or SEQ ID NO:24 have at least 90% identity based on the Clustal alignment method.

18. The polypeptide of claim 16, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, or SEQ ID NO:24.

19. The polypeptide of claim 16, wherein the polypeptide is a sucrose transport protein.

20. A chimeric gene comprising the polynucleotide of claim 11 operably linked to a regulatory sequence.

Q2

21. An expression vector comprising the polynucleotide of claim 11.

22. A method for transforming a cell comprising transforming a cell with the polynucleotide of claim 11.

23. The cell produced by the method of claim 22.

Cancelled

24. An isolated polynucleotide comprising a nucleotide sequence comprised by the polynucleotide of claim 11, wherein the nucleotide sequence contains at least 30 nucleotides.

Add D3

REMARKS

Claims 1-10 have been cancelled, and claims 11-24 have been added. Claims 11-24 are pending. It is respectfully requested that the amendments above be entered before examination of the application.

Support for sequence identities of 90% and 95% is found on page 5, lines 23-26 of the specification. Support for claim 26 is found on page 6, lines 4-8 of the specification.

Please charge the necessary fees to Deposit Account 04-1928 (E. I. du Pont de Nemours and Company). If the fee is insufficient or incorrect, please charge or credit the balance to the above-identified account.

In view of the foregoing, allowance of the above-referenced application is respectfully requested.

Respectfully submitted,

Thomas M. Rizzo

THOMAS M. RIZZO
ATTORNEY FOR APPLICANTS
REGISTRATION NO. 41,272
TELEPHONE: 302-892-7760
FACSIMILE: 302-892-1026

Dated: October 5, 2000